Details

Autor(en) / Beteiligte

• Valle, Luca F.
• Jiang, Tommy
• Weiner, Adam B.
• Reiter, Robert E.
• Rettig, Matthew B.
• Shen, John
• Chang, Albert J.
• Nickols, Nicholas G.
• Steinberg, Michael L.
• Kishan, Amar U.

Titel

Multimodality Therapies for Localized Prostate Cancer

Ist Teil von

• Current oncology reports, 2023-03, Vol.25 (3), p.221-229

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose of Review Multimodality therapy including radical prostatectomy, radiation therapy, and hormone therapy are frequently deployed in the management of localized prostate cancer. We sought to perform a critical appraisal of the most contemporary literature focusing on the multimodality management of localized prostate cancer. Recent Findings Men who are ideal candidates for multimodality therapy include those with unfavorable intermediate-risk disease, high-risk disease, and very high-risk disease. Enhancements in both systemic agents (including second-generation antiandrogens) as well as localized therapies (such as stereotactic body radiotherapy and brachytherapy) are refining the optimal balance between the use of systemic and local therapies for localized prostate cancer. Genomic predictors are emerging as critical tools for more precisely allocating treatment intensification with multimodality therapies as well as treatment de-intensification. Summary Close collaboration among medical oncologists, surgeons, and radiation oncologists will be critical for coordinating evidence-based multimodality therapies when clearly indicated and for supporting shared decision-making in areas where the evidence is mixed.